The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC).
M. R. Khawaja
No relevant relationships to disclose
A. Younger
No relevant relationships to disclose
J. M. Funke
No relevant relationships to disclose
M. J. Waddell
No relevant relationships to disclose
D. R. Jones
No relevant relationships to disclose
K. Pollok
No relevant relationships to disclose
N. K. Prasad
No relevant relationships to disclose
W. Berry
No relevant relationships to disclose
G. Sandusky
No relevant relationships to disclose
E. G. Chiorean
Research Funding - Novartis